Set up to support Amgen's global biopharmaceutical business, the centre, based in Lisbon, represents an estimated investment of €100 million in the country over the next five years.

The deal was reached "for an acquisition price of €250 million paid at closing and a success fee to be paid to the sellers over 2023-28," announced EDP this Thursday.